Compare PepsiCo, Inc. (PEP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? PepsiCo, Inc. trades at $135.84 (market cap $184.26B), while State Street SPDR S&P Biotech ETF trades at $152.06. The key difference: PepsiCo, Inc. pays a 4.39% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, PepsiCo, Inc. nearer its low. Which is the better fit depends on your goals.
| PEP | XBI | |
|---|---|---|
Market Cap | $184.26B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $170.44 | $164.28 |
52-Week Low | $134.98 | $85.16 |
Enterprise Value | $226.76B | — |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $134.98, down 0.35% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025 with a net income margin of 10.78%, and it has beaten EPS estimates in the last three quarters. Recent news highlights price cuts on snacks like Doritos after consumer pushback and the termination of a music festival sponsorship.
The outlook is mixed: analyst consensus is a buy with a $158.79 price target, but near-term risks include competitive pressures and execution of the North American turnaround. Earnings growth and margin expansion from cost initiatives remain key catalysts for upside, though high valuation ratios and debt levels warrant caution.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
